Based on the two major technological platforms of zebrafish and organoids, Hunter Bio has developed a comprehensive precision medicine solution with a distinctive "in vivo (zebrafish PDX model) + in vitro (organoid model)" mode.

The zebrafish PDX model involves transplanting fresh tumor tissues from patients into zebrafish, culturing the tumor tissues in the zebrafish's microenvironment, administering potential drugs to the zebrafish, and rapidly evaluating the anti-cancer drug efficacy after metabolism and absorption. Ultimately, this model helps to select the most suitable treatment plan for patients, assisting in clinical precision personalized medicine. The zebrafish PDX model has many advantages, such as high success rate, fast, intuitive visualization, and low cost.

patient-derived organoids are three-dimensional models established through the in vitro 3D culture system using fresh tumor tissues from patients. These models highly resemble the pathological histology features, molecular characteristics, and drug sensitivity of patient tumors.

Hunter Bio has achieved a combination of the zebrafish PDX model and the organoid model, allowing for rapid screening of clinical treatment plans for tumors and making cancer treatment more precise and effective.

Tumor organoids and zebrafish PDX models serve as "drug substitutes" for cancer patients, accurately evaluating the effectiveness of chemotherapy drugs, targeted drugs, and various combination therapy options. They have the characteristics of high throughput and high specificity, providing a basis for precision medicine for cancer patients.

Tumor Drug Sensitivity Testing Based on Organoids

Tumor tissues taken from patients are cultured into 3D cell models, and the efficacy of anti-tumor drugs is quickly evaluated in vitro, providing real-time feedback on the response of patient tumor samples to different drugs.

Tumor drug sensitivity testing based on zebrafish PDX

Patient tumor tissues are transplanted into zebrafish to construct the zebrafish PDX model. This in vivo model is used to rapidly evaluate the efficacy of anti-tumor drugs and provide real-time feedback on the response of patient tumor samples to different drugs.